Q1 Earnings Forecast for Longeveron Issued By Roth Capital

Longeveron Inc. (NASDAQ:LGVN) – Equities research analysts at Roth Capital issued their Q1 2026 EPS estimates for shares of Longeveron in a report issued on Monday, March 3rd. Roth Capital analyst B. Pachaiyappan forecasts that the company will post earnings per share of ($0.43) for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. Roth Capital also issued estimates for Longeveron’s Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($1.86) EPS.

A number of other analysts have also recently issued reports on LGVN. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Longeveron in a research report on Monday. Roth Mkm began coverage on Longeveron in a report on Friday, December 6th. They set a “buy” rating and a $10.00 price target for the company.

Longeveron Stock Performance

Shares of NASDAQ:LGVN opened at $1.40 on Wednesday. The company has a 50-day simple moving average of $1.64 and a 200 day simple moving average of $1.89. The company has a market capitalization of $20.77 million, a P/E ratio of -0.22 and a beta of 0.36. Longeveron has a 52-week low of $0.77 and a 52-week high of $6.40.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. State Street Corp acquired a new position in shares of Longeveron in the third quarter valued at approximately $29,000. Geode Capital Management LLC boosted its stake in Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after purchasing an additional 97,953 shares during the period. Virtu Financial LLC acquired a new position in Longeveron in the 4th quarter valued at $53,000. Northern Trust Corp acquired a new position in Longeveron in the 4th quarter valued at $31,000. Finally, Jane Street Group LLC bought a new position in Longeveron during the 4th quarter worth $35,000. 10.01% of the stock is owned by institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.